Good MorningA much-needed market correction is underway and may not end soon. The sell-off was sparked by a sell-the-news event that has yet to play out. The news was the June CPI report, which was affirmed by the PCE price index; consumer inflation is falling closer to the FOMC's target of 2%, paving the path toward an interest rate cut. The significant detail is the interest rate cut, a move that will signal the easing of economic headwinds and a pivot for the market. That pivot will be into small and mid-cap names, driven by the expectation improving business conditions will drive growth and profits.
This week's risk is the FOMC. The FOMC is meeting on Tuesday and Wednesday and will release a fresh policy statement on Wednesday. The market is pricing in a rate cut for August and a high probability for a second in September. Still, the FOMC may hesitate to commit, inducing volatility in the market. The takeaway is that underlying economic conditions and outlook remain bullish; a stock market correction should result in a buy-the-dip opportunity and fresh all-time highs later this year. Featured: SAGA Metals nears a key milestone in critical minerals race (Ad) 
|
Technology | | The earnings reports from Alphabet Inc. (NASDAQ: GOOGL) and Tesla Inc. (NASDAQ: TSLA) led technology stocks lower for the week. Some analysts are warning that the price action is due to an artificial intelligence (AI) bubble, but there could be other factors at play.
First, the second half of Jul... Read the Full Story |
|
From Our Partners | | Barrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldrush, and Cortez Hills, deposits that could hold up to 60 million ounces of gold.
One overlooked explorer controls 142 claims bordering Fourmile and sitting less than a mile from Goldrush. New geological modeling aims to reveal what's beneath this largely untested ground, while a planned 5% royalty spin-off could give shareholders a separate stake in the project. | | Read the full report before the next catalyst hits |
|
Technology | | The world of cryptocurrency is still a developing thesis, with some raging bulls on every coin out there and others calling the asset class a complete scam and Ponzi scheme. Whether one side is right or wrong is up for debate, but one thing remains true: investor and trader psychology and behavior.
... Read the Full Story |
|
Technology | | Owning stock gives investors a one-for-one behavior in the underlying stock, and that’s good enough when there is a longer timeframe. But it won’t cut it for big traders looking to quickly get a hit-and-run stock move.
That’s where stock options come in. They allow investors to ac... Read the Full Story |
|
From Our Partners | | Trader Chris Pulver says a new SEC document dropping the day-trading limit to $2,000 has created the biggest retail opportunity he has seen in over 30 years.
His strategy targets what he calls Flashpoints - moments when market makers must move billions of dollars on the S-P 500 in a narrow window. Research shows one recent signal would have returned 83.7% in 36 minutes and another 62.8% in 51 minutes.
Lance Ippolito flew to Utah for a full breakdown of the method. | | Tap here to see the complete Flashpoint trading breakdown now |
|
Industrials | |
3M’s (NYSE: MMM) rebound is gaining momentum because of surprisingly good results. Today’s story is that repositioning efforts are taking hold and driving improved profitability while litigation risks dwindle. The takeaways from the Q2 report include better-than-expected top and bottom... Read the Full Story |
|
Markets | |
Some names in the retail and apparel sectors have made a splash in investors’ monitors in recent weeks, even months. Unfortunately, the attention is founded on seriously bearish price action, like the fact that shares of Lululemon Athletica Inc. (NASDAQ: LULU) are now trading at only 48% of ... Read the Full Story |
|
From Our Partners | | A 20-minute read could change how you approach your next options trade. Chris Pulver is giving away his guide, Right About The Market, Wrong About The Money, free of charge.
Built from two decades of trading experience, the guide tackles a common problem: losing a trade even when your market call was correct.
No cost, no catch, just a packed resource for options traders who want a sharper edge. | | Click here to get your free copy of the guide |
|
Technology | |
As earnings season unfolds and several mega-cap tech stocks, including members of the "Magnificent Seven," have reported, the overall market and tech sector have seen significant declines in recent weeks. The XLK technology sector ETF has dropped nearly 6% this month and is now down over 10% from ... Read the Full Story |
|
Technology | |
ServiceNow Inc. (NYSE: NOW), a leading provider of cloud-based software solutions, has recently made headlines with a notable 15% surge in its stock price following a strong earnings report.
This impressive gain brings its year-to-date performance to nearly 20%, and the stock has just broken o... Read the Full Story |
|
Healthcare | |
Molina Healthcare, Inc. (NYSE: MOH) is a leading provider of managed healthcare services, primarily focusing on government-sponsored programs such as Medicaid and Medicare. Molina Healthcare’s earnings report for the second quarter was released, and it sent shockwaves through the market, p... Read the Full Story |
|
Markets | |
AstraZeneca PLC (NASDAQ: AZN) is a United Kingdom-based healthcare firm and the sixth-largest pharmaceutical company in the world by market capitalization. So far, in 2024, the firm has outperformed the market and its sector, achieving a total return of 17%. The total return of the SPDR S&P ... Read the Full Story |
|
Healthcare | |
Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company known for its focus on developing novel treatments for metabolic and endocrine disorders. Viking Therapeutics' earnings report for the second quarter of 2024 was impressive, capturing the attention of investors and ... Read the Full Story |
|
Monday's Early Bird Stock Of The Day Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. | Should I Buy Edwards Lifesciences Stock? EW Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Edwards Lifesciences was last updated on Friday, August 28, 2026 at 6:35 PM.
Edwards Lifesciences Bull Case -
The current stock price is around $89, which is near its 50-day moving average, indicating potential stability in the short term.
-
Edwards Lifesciences Co. reported a significant increase in revenue, up 13.6% compared to the same quarter last year, showcasing strong growth potential.
-
The company has a low debt-to-equity ratio, suggesting a strong balance sheet and lower financial risk, which can be attractive to investors.
-
With a return on equity of 15.68%, Edwards Lifesciences Co. demonstrates effective management in generating profits from shareholders' equity.
-
Analysts have a positive outlook, with many rating the stock as a "Buy" and setting price targets above the current stock price, indicating potential for appreciation.
Edwards Lifesciences Bear Case -
The price-to-earnings ratio is relatively high at 52.26, which may indicate that the stock is overvalued compared to its earnings.
-
Despite recent revenue growth, the company has set conservative earnings guidance for Q3 2026, which may signal caution about future performance.
-
Insider selling activity has been noted, with executives selling shares, which could raise concerns about their confidence in the company's future prospects.
-
The beta of 0.85 suggests that the stock is less volatile than the market, which may limit potential high returns for aggressive investors.
-
Market conditions and competition in the medical technology sector could pose risks to sustained growth and profitability for Edwards Lifesciences Co.
| | View Today's Stock Pick |
|
